
Abstract
Background: We aimed to verify safety and effectiveness of certoparin real-world use and to identify predictors of thromboembolic events or bleeding. Methods: This was a non-interventional study documenting patients at hospital-or office-based physicians. Results: Patients' (n = 1407) mean age was 53.7 +/- 16.1 years. Reason for certoparin use was prophylaxis of venous thromboembolism in 1331 (94.6%) patients and treatment in 76 (5.4%) patients. In only 11.4% of those receiving prophylaxis and 13.2% of those receiving treatment dosing, duration and schedule of certoparin were within label. There were 2 patients with deep venous thrombosis (DVT], no pulmonary embolism PE]), and 51 patients (3.8%) with minor (nonmajor) bleeding complications in patients receiving prophylaxis. Two patients treated with certoparin had recurrent DVT and one had PE (one patient with minor bleeding). Conclusions: Certoparin is very effective in real world. This also applies to patients in whom clinical decision making leads to an alteration of recommended application.
Item Type: | Journal article |
---|---|
Form of publication: | Publisher's Version |
Keywords: | anticoagulation; certoparin; thromboembolism; bleeding; real world |
Faculties: | Medicine |
Subjects: | 600 Technology > 610 Medicine and health |
URN: | urn:nbn:de:bvb:19-epub-23822-0 |
ISSN: | 1076-0296 |
Alliance/National Licence: | This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively. |
Language: | English |
Item ID: | 23822 |
Date Deposited: | 11. Mar 2015, 11:16 |
Last Modified: | 04. Nov 2020, 13:05 |